GenScript Biotech's CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity to LaNova Medicines, enhancing its portfolio while allowing LaNova to advance its immunotherapy pipeline.
Information on the Target
GenScript Biotech's subsidiary, ProBio, is a prominent Contract Development and Manufacturing Organization (CDMO) recognized for its innovative capabilities in the biotechnology sector. The company specializes in developing advanced therapies and services aimed at accelerating the commercialization of biopharmaceuticals.
The recent licensing of its PD-1 new molecular entity (NME) to LaNova Medicines marks a significant advancement in ProBio's portfolio, highlighting their expertise in immunotherapy and their commitment to developing groundbreaking treatments for cancer.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The biotechnology industry in China has experienced rapid growth in recent years, driven by increased investment in research and development. As one of the
Similar Deals
Adicon Holdings Limited → Crown Bioscience Inc.
2026
LaNova Medicines
invested in
ProBio
in 2025
in a Other deal